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Abstract  
Purpose of Review The aims of this meta-analysis were to investigate the effects of orally-administered isolated 
taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans. Recent 
Findings There is growing evidence that taurine deficiency is associated with hypertension and that oral 
supplementation can have antihypertensive effects in humans. However, these investigations have been 
conducted across a number of decades and populations and have not been collectively reviewed. A search was 
performed using various databases in May 2018 and later screened using search criteria for eligibility. There 
were seven peer-reviewed studies meeting the inclusion criteria, encompassing 103 participants of varying age 
and health statuses. Taurine ingestion reduced SBP (Hedges’ g = -0.70, 95% CI -0.98 to -0.41, P < 0.0001) and 
DBP (Hedges’ g = -0.62, 95% CI -0.91 to -0.34, P < 0.0001). These results translated to mean ~ 3 mmHg 
reductions in both SBP (range = 0-15 mmHg) and DBP (range = 0-7 mmHg) following a range of doses (1 to 6 
g/day) and supplementation periods (one day to 12 weeks), with no adverse events reported. Summary These 
preliminary findings suggest that ingestion of taurine at the stated doses and supplementation periods can reduce 
blood pressure to a clinically-relevant magnitude, without any adverse side-effects. Future studies are needed to 
establish the effects of oral taurine supplementation on targeted pathologies and the optimal supplementation 
doses and periods.   
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Introduction 
Hypertension adversely affects public health worldwide and is a leading cause of cardiovascular and kidney 
disease [1]. As a major attributable cause of morbidity and mortality, hypertension significantly adds to the 
global disease burden [2]. Nutritional and lifestyle interventions are recognised as primary strategies for the 
prevention of hypertension and can reduce subsequent cardiovascular risk [3,4]. Non-pharmacological 
management of hypertension is typically preferred for blood pressure control [5] to avoid the cost and potential 
side-effects associated with chronic drug therapy [6]. However, pharmacological intervention is often necessary 
to elicit the desired control of blood pressure [7] but can be administered alongside secondary control measures 
to achieve the desired clinical outcomes [8].   
Oral taurine can be supplemented through dietary sources or in isolated form and has been considered as a 
potential antihypertensive intervention [9]. Taurine is a sulfonic acid, found in both skeletal and cardiac 
myocytes in high concentrations [10]. While taurine can be synthesized from methionine and cysteine in 
mammals, it is also derived from food sources [11]. As a free, non-proteinogenic acid, it has capacity to take 
part in many intra- and extra-cellular biological processes – some of which have profound effects on organ-level 
physiology [12]. For example, taurine has antiarrhythmic, chronotropic and inotropic effects and has been 
suggested to reduce blood pressure [13]. Furthermore, the taurine transporter (TauT) is abundantly expressed in 
vascular smooth muscle [14], which supports its putative role as a vaso-relaxant in the control of vascular 
function [15]. The antihypertensive effects of taurine are attributed to its sympatholytic action on the central 
nervous system [16] and suppression of angiotensin II, which is a known stimulus of water retention in the 
development of cardiac preload [17]. The combination of these actions is thought to facilitate the hypotensive 
actions of taurine but studies are frequently limited to either in-vitro cell preparations or animal investigations 
and are seldom explored in humans. As such, it is necessary to evaluate the published evidence to establish an 
understanding of taurine’s effect on blood pressure in humans.  
 
A WHO-coordinated Cardiac Diseases and Alimentary Comparison (CARDIAC) study, conducted across 60 
separate populations from 22 countries, has reported inverse relationships between 24-h urinary taurine 
excretions and blood pressure, indicating a link between taurine deficiency and hypertension [18**]. Indeed, the 
popularity of taurine supplementation as an alternative therapy for mild-to-severely hypertensive patients has 
become increasingly apparent in recent years [9,10,17]. It is important to recognise the effects of oral taurine 
supplementation among humans, since the transfer of findings from rodent or in-vitro studies remains 
speculative. Thus, it is necessary to understand whether tolerable doses of orally-administered taurine can 
reduce blood pressure and confer cardio-protective effects. Therefore, this study systematically reviewed and 
meta-analysed all peer-reviewed studies that have provided human subjects with isolated taurine, with the 
intention of reducing resting blood pressure. Specifically, the aims of this meta-analysis were to investigate the 
effects of orally-administered isolated taurine on resting SBP and DBP in humans.  
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Methods 
Search strategy  
All literature investigating the effects of oral taurine on blood pressure was searched and obtained using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines, with a 
pre-determined search strategy [19]. There was no limit on the status or language of the publication and the final 
searches were performed in PubMed and Science Direct on 30.05.2018. The search terms independently used 
were ‘taurine AND blood pressure’, ‘taurine AND hypertension’ or ‘taurine AND cardiovascular’.  
 
Study selection 
Following the initial identification of articles, two reviewers (MW and OJ) screened the titles and abstracts for 
inclusion, removing any duplicates. The reference lists of the initial papers were reviewed independently by two 
authors (MW and OJ). The remaining articles were then assessed by MW and OJ against the initial search 
criteria. To be included in this analysis, the studies must have: i) administered oral taurine to humans of any age 
or health status, without co-ingestion with other dietary supplements; ii) evaluated resting systolic and diastolic 
blood pressure and iii) be placebo-controlled. Of the remaining papers, some were further removed for the 
reasons outlined in Fig. 1. In part, this included papers that had co-ingested taurine with other supplements, such 
as caffeine.  
 
*****Insert Fig. 1 near here***** 
 
2.3 Data extraction and quality assessment  
Data were extracted independently by two authors (MW and OJ) and entered into a custom excel spreadsheet. 
Collected data included: i) characteristics of the sample (sex, health status, age, activity status); ii) study design; 
iii) taurine dose; iv) duration of supplementation; v) post-intervention outcomes of systolic and diastolic blood 
pressure; and vi) bias. Risk of bias was assessed by two authors (MW and OJ) according to Cochrane 
collaboration guidelines [20]. Publication bias was also accounted for by plotting the effect size as a percentage 
against the standard error (SE) for each study. 
 
2.4 Statistical analysis 
Data analyses were performed by one author (MW). Raw data were extracted in the form of a mean, SD and 
sample size for the meta-analysis. Publicly available software (WebPlotDigitizer, Version 3.12) was used to 
extrapolate any unreported values from figures to raw mean and SD data. The overall meta-analysis of 
endurance performance was performed in RevMan 5.3, Cochrane Collaboration, Oxford, UK), including all 
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seven of the final studies. The effect sizes and inverse-variance weights were calculated according to published 
equations Lipsey and Wilson [21]. Data were analysed with a fixed-effects model, with heterogeneity assessed 
using the I2 statistic. Hedges’ g and 95% confidence intervals were used to express the standardised mean 
differences between taurine and placebo groups across studies. The magnitudes of the effects were assessed 
based on the thresholds of: 0.2, 0.5 and 0.8 for small, moderate and large, respectively [22]. Statistical 
significance was set at P < 0.05 for all analyses.   
 
2. Results 
3.1 Study selection 
The initial searches retrieved 7,568 articles. After screening articles to remove reviews, duplicates and animal 
studies, 57 full-text articles remained. Searches of their reference lists did not reveal any missing papers. On the 
basis of the inclusion criteria, 50 articles were removed from the 57. Therefore, seven papers were included in 
the final meta-analysis (Fig. 1). Three of the removed papers met all of the inclusion criteria except for one, 
such as the use of placebo control [23] or not reporting both systolic and diastolic pressure [24].  
 
3.2 Study characteristics 
The characteristics of the seven included studies are summarized in Table 1. The studies included a total of 103 
participants, comprising both males and females of varying age, training and health status. Four of the studies 
recruited participants > 50 years, while four investigated patients with an ongoing clinical condition (i.e. type I 
diabetes, liver cirrhosis or heart disease). Five of the studies were independent groups designs, whilst two were 
cross-over designs. The range of taurine that was orally administered across studies was 1 g/day to 6 g/day, with 
four studies providing ~1.5 g daily. Only one study provided an acute (single dose), while six studies gave 
chronic (multiple doses > 1 day), with 12 weeks being the longest supplementation period. There were no 
adverse events noted in any of the studies, beyond that reported in the control groups.  
 
*****Insert Table 1 near here***** 
 
3.3 Meta-analysis 
The results of the overall meta-analyses for SBP and DBP are reported in Fig. 2 and Fig. 3, respectively. 
Overall, there was a ‘moderate’ improvement in systolic blood pressure with taurine compared to placebo 
(Hedges’ g = -0.70, 95% CI = -0.98 to -0.41, P < 0.0001). The I2 statistic demonstrated 0% heterogeneity (P = 
0.620). The meta-analysis for diastolic blood pressure also showed a moderate effect of taurine (Hedges’ g = -
0.62, 95% CI = -0.91 to -0.34, P < 0.0001), with 0% heterogeneity (I2, P = 0.500).  
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*****Insert Fig. 2 near here***** 
*****Insert Fig. 3 near here***** 
 
3.4 Risk of bias 
The studies included had a generally low or unclear risk of bias. Most studies indicated a random allocation 
procedure but failed to provide the exact randomisation process or the way in which allocation to groups was 
concealed. Fig. 4 and Fig. 5 show that publication bias analysis (standard mean differences and standard error 
relationship) was symmetrical, with no outliers for SBP and DBP, respectively.  
 
*****Insert Fig. 4 near here***** 
*****Insert Fig. 5 near here***** 
 
3. Discussion 
The main finding of this meta-analysis was that taurine significantly reduced both resting systolic and diastolic 
blood pressure by a ‘moderate’ magnitude. In absolute terms, the mean change in blood pressure across the 
studies was ~ 3 mmHg for both systolic and diastolic measurements, ranging between 0-15 mmHg and 0-7 
mmHg, respectively. A change of this magnitude is considered to be clinically meaningful [7] and could 
significantly lower the risks of cardiovascular (CVD) and kidney disease. Indeed, reductions in SBP and DBP of 
> 2 mmHg can reduce the incidence of CVD by ~ 6% in both hypertensive and normotensive individuals [5]. 
The effect sizes noted herein are similar to those reported for a range of other dietary supplements, such as 
beetroot juice [32] (Systolic ~ 4 mmHg, Diastolic ~ 1 mmHg) or many classes of pharmacological interventions, 
such as angiotensin II receptor blockers [33] (Systolic ~ 2 mmHg, Diastolic ~ 0.2 mmHg), diuretics [34] 
(Systolic ~ 6 mmHg, Diastolic BP ~ 2 mmHg) and angiotensin-converting enzyme (ACE) inhibitors [35] 
(Systolic ~ 5 mmHg, Diastolic ~ 3 mmHg). Furthermore, unlike some of the above examples, there were no 
reported adverse side-effects of taurine ingestion, despite the range of doses (1.5 g/day – 6 g/day) and length of 
supplementation periods (1 day – 12 weeks). Collectively, these preliminary findings suggest that ingestion of 
taurine across the above ranges and supplementation periods, which are markedly below the 10 g/day upper 
tolerable limit [36], can reduce blood pressure by a clinically-relevant magnitude.   
 
The roles of taurine in the control of blood pressure are more comprehensively understood in the animal, rather 
than human model, yet some of the ascribed mechanisms could be feasibly shared. For example, the vaso-
relaxant properties of taurine have been demonstrated in rodents [37-39], porcine [40] and the leporidae family 
[41], which has been more recently revealed in isolated human aortic rings [15]. The collective reasoning 
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provided across the literature attributes these findings to taurine’s direct actions on potassium channels, situated 
in the smooth muscles or endothelial cells of the vasculature. Likewise, lower urinary norepinephrine excretion 
has been observed following taurine administration in humans, thus indicating the suppression of the 
sympathetic nervous system [24]. This supports the frequently reported reductions in sympathetic tone or 
attenuated over-activity of the sympathetic nervous system following taurine administration in animal studies 
[27,42-43]. One study included in the current meta-analysis [30*], which has provided some of the most 
convincing data to support the antihypertensive effects of taurine supplementation to date, reported an increased 
plasma hydrogen sulphide (H2S) level, which correlated with a reduction in blood pressure. The vasodilatory 
role of H2S has been previously described by Tian and colleagues [44] via its activation of ATP-sensitive 
potassium channels in rat coronary arteries and would explain the observed effects on blood pressure. 
Interestingly, perhaps the most commonly reported hypotensive mechanism of taurine in animal models is 
angiotensin II antagonism [45], which mimics the action of some prescribed drug therapies; however, to the best 
of the authors’ knowledge, this has not been investigated among humans.   
 
The current literature describes the abundance of free taurine in human tissues and its involvement in the normal 
functioning of major physiological systems. Whilst many of these potential mechanisms could help to reduce 
blood pressure, it remains unclear whether the efficacy of taurine supplementation is reliant on the health status 
or age of the participants, which might influence the taurine content of various bodily tissues, such as that of the 
cardiovascular system. Unfortunately, the diverse characteristics of the meta-analysed participants included here 
do not facilitate the direct investigation of these questions. Nevertheless, the pre-established relationships 
between taurine deficiency and age [46], heart disease [47], hypertension [18**] and diabetes [48] indicate that 
features of these conditions are partly explained by a pre-existing taurine deficiency, as indicated by higher 24-h 
urinary taurine excretion rates. In the resting state, young healthy participants are likely to have a sufficient 
content of taurine stored in muscle tissue [12,49], which would infer a redundancy of taurine supplementation 
among these participants. However, there are two studies included in the current meta-analysis with young (< 30 
years), normotensive participants [28,31], where contrasting results are reported. For example, Moloney and 
colleagues [31] investigated 2 weeks of taurine supplementation among type I diabetic patients and found no 
change in blood pressure, while Warnock et al. [28] provided a single acute dose of taurine and reported a mean 
reduction of 7 mmHg systolic pressure. An apparent differentiating factor between these two studies was the 
baseline blood pressure values, which were surprisingly low (~ 100/86 mmHg) among the young diabetic cohort 
[31], yet borderline hypertensive (~ 127/73 mmHg) among the young healthy cohort [28]. Furthermore, despite 
no change in blood pressure, taurine supplementation reversed endothelial dysfunction and arterial stiffness in 
conduit vessels of the diabetic group [31], indicating that taurine supplementation targeted pathological changes 
in the cardiovascular system, without altering arterial pressure. Therefore, it is possible that the effects of taurine 
supplementation on blood pressure are pronounced among pre-hypertensive or hypertensive participants and do 
not affect those with normal or moderately low blood pressure, irrespective of their health status. Further 
research is clearly required to extend the preliminary summary of studies provided here to establish the 
populations that are most likely to benefit from taurine supplementation.   
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It was apparent that most studies selected to provide repeated, long-term doses of taurine (> 1 day; Table 1), 
rather than acute administration (≤ 1 day). The reasons for this are unclear but two recent meta-analyses have 
identified that acute taurine supplementation was sufficient to improve endurance exercise performance [50-51], 
which among other factors, depends upon the capacity and efficiency of the cardiovascular system. Indeed, 
some studies have showed a concomitant reduction in heart rate following acute taurine supplementation [28, 
52] and taurine-containing energy drinks are known to increase stroke volume in humans [53]. Furthermore, 
taurine has a short half-life and one week of supplementation does not alter skeletal muscle content in healthy 
participants [54]. Given these short-term effects in apparently healthy participants, the rationale for repeated 
ingestion is not entirely clear but would presumably target taurine deficient patients only, based on the theory 
that continuous ingestion will augment endogenous storage. There was an insufficient amount of articles 
available to perform a sub-analysis of acute and chronic supplementation regimes or populations, highlighting 
the need for further research in this area. Evidence-based guidelines for the optimal supplementation periods and 
dosages of oral taurine for the purpose of cardio-protection are yet to be determined, yet are necessary to 
develop the applicability of fundamental research conducted across the last ~ 30 years. Indeed, a long-term diet 
rich in taurine might offset hypertension to a similar magnitude, yet this has not been empirically explored.     
 
The risk of bias across the studies included in this meta-analysis was generally low, with minor exceptions for 
‘unclear’ risks of random allocation procedures and allocation concealment (Fig. 2 & 3). However, there were 
other papers not included in the meta-analysis for basic scientific reasons, such as lack of control groups (i.e. 
[23]) or incomplete reporting of outcome variables [24]. This is unfortunate, as the addition of these papers 
might have strengthened the overall effects of taurine on blood pressure; however, this highlights the need for 
more detailed and rigorous research design in this area. In addition, it is possible that certain populations have 
been underrepresented across the available meta-analysed studies. The studies were conducted in Europe [28-
29,31], Asia [27,30] and the Middle East [25-26], yet there were no studies conducted in larger continents, such 
as the North and South America, Africa or Australasia, where similar risks of mortality due to cardiovascular 
disease are present and increased in certain ethnic groups [55]. This could be partly addressed with changes in 
dietary supplementation, including changes in taurine intake. Indeed, there are markedly different dietary habits 
between populations of the same country and taurine deficiency, as a result of an unintentionally low taurine 
diet, has been associated with hypertension [56]. A larger number of studies are needed in these 
underrepresented geographical areas to ascertain the validity of these association studies on a global scale.   
 
Conclusions 
Given the small number of studies meta-analysed, our data should be considered as a preliminary assessment of 
the antihypertensive effects of oral taurine supplementation. Nevertheless, a mean ~ 3 mmHg (range 0-15 
mmHg) change in SBP across 103 participants represents a substantial contribution towards the 5 mmHg  
reductions in SBP that were estimated to decrease the risk of mortality due to stroke by 14% and mortality from 
cardiovascular diseases by 9% [7]. Furthermore, it is noteworthy that there have been no adverse events 
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associated with taurine ingestion, indicating its tolerability among human participants. The studies included in 
this meta-analysis included a range of subjects, from young healthy and recreationally active, to elderly and 
diseased, thus confirming the wider application of taurine supplementation but restricting the understanding of 
taurine’s therapeutic role in target pathologies. Research is required to establish the correct taurine doses and 
supplementation periods required for the management of cardiovascular disease or associated risk factors. 
Further studies investigating dietary sources of taurine and their influence on risk factors of cardiac disease are 
required to provide more comprehensive evidence of taurine’s health benefits. 
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Figure legends 
Fig. 1 Overview of the systematic review and study selection process 
Fig. 2 Effect of taurine on resting systolic blood pressure. Green circles = low risk of bias; red circles = high 
risk of bias; blank spaces = unclear risk of bias. A = random sequence generation; B = allocation concealment; 
C = blinding of participants and personnel; D = blinding of outcome assessment; E = incomplete outcome of 
data; F = selective reporting bias; G = other bias.  
Fig. 3 Effect of taurine on resting diastolic blood pressure. Green circles = low risk of bias; red circles = high 
risk of bias; blank spaces = unclear risk of bias. A = random sequence generation; B = allocation concealment; 
C = blinding of participants and personnel; D = blinding of outcome assessment; E = incomplete outcome of 
data; F = selective reporting bias; G = other bias.  
Fig. 4 Risk of bias for resting systolic blood pressure, determined by the relationship between standard mean 
difference (SMD) and standard error (SE) of the SMD. 
Fig. 5 Risk of bias for resting diastolic blood pressure, determined by the relationship between standard mean 
difference (SMD) and standard error (SE) of the SMD. 
 
Table titles 
Table 1 Summary of studies included in the meta-analysis for the effects of taurine on resting blood pressure (n 
= 7)  
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